- Dr. Mackey formerly served as Senior Vice President of Pfizer
Worldwide Research and Development and as Director of Pfizer's La
Jolla Laboratories
SOUTH
SAN FRANCISCO, Calif., April 6,
2022 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of
Directors.
Dr. Mackey brings over 30 years of life sciences research,
development and operational experience to IDEAYA. As Senior Vice
President of Pfizer Worldwide Research and Development and Director
of Pfizer La Jolla Laboratories, she established a premier research
and development capability and a robust drug pipeline of oncology
therapeutics, including sunitinib (Sutent), axitinib (Inlyta),
crizotinib (Xalkori) and palbociclib (Ibrance). She earlier served
as Pfizer's Head of Strategic Alliances and Genomic and Proteomic
Sciences.
Dr. Mackey also has considerable relevant experience as a Board
Director of several public and private companies. She currently
serves as a Director of AVID Bioservices, Rady Children's Hospital
and Rady Children's Institute of Genomic Medicine, and as Chairman
of the Board of Directors of Cour Pharma, a privately held,
clinical stage immunology company. She previously served as a
Director on the Boards of Trillium Therapeutics, Poseida
Therapeutics, GW Pharma, Evolve Biosystems, Sequenom, Viventia Bio,
YM Biosciences and Althea Technologies.
"Catherine's extensive oncology research and development
experience will be invaluable to IDEAYA as we enhance our industry
leading synthetic lethality platform and advance our
first-in-class synthetic lethality pipeline targeting
genetically-defined patient populations," said Yujiro S. Hata, President and Chief Executive
Officer, at IDEAYA Biosciences.
"I am pleased to join IDEAYA as it targets multiple clinical
milestones, including advancing its Phase 1 MAT2A inhibitor IDE397
into monotherapy expansion and clinical combination cohorts, and
obtaining regulatory feedback for its Phase 2 PKC inhibitor
darovasertib on a potential registration-enabling study," said Dr.
Mackey. "IDEAYA's late-stage preclinical pipeline is also maturing
with potential first-in-class PARG and Pol Theta programs
targeting IND-enabling studies."
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates capabilities in
identifying and validating translational biomarkers with drug
discovery to select patient populations most likely to benefit from
its targeted therapies. IDEAYA is applying its early research and
drug discovery capabilities to synthetic lethality – which
represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i)
monotherapy expansion and clinical combination of IDE397, (ii)
obtaining regulatory feedback for darovasertib, and (iii)
IND-enabling studies for PARG and Pol Theta. IDEAYA undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's Annual Report on Form
10-K filed on March 18, 2022, and any
current and periodic reports filed with the U.S. Securities and
Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-catherine-mackey-phd-to-its-board-of-directors-301518507.html
SOURCE IDEAYA Biosciences, Inc.